Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment

BACKGROUND: To compare the efficacy and tolerability of intravitreal ranibizumab (IVR) 0.5 mg or 0.3 mg with non-anti-vascular endothelial growth factor (VEGF), and to compare the efficacy of IVR 0.5 mg with IVR 0.3 mg in the treatment of macular edema secondary to retinal vein occlusion. METHODS: R...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Wei-tao, Xia, Xiao-bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381461/
https://www.ncbi.nlm.nih.gov/pubmed/25881069
http://dx.doi.org/10.1186/s12886-015-0017-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381461/
https://www.ncbi.nlm.nih.gov/pubmed/25881069
http://dx.doi.org/10.1186/s12886-015-0017-z

Ejemplares similares